Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05856448 | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus | PHASE2 | COMPLETED | 186 | — | — | Jun 28, 2023 | Feb 27, 2026 | May 14, 2026 | 84 | United States, Argentina +10 |
| Arm | Type | Description |
|---|---|---|
| GLPG3667 - Treatment A | EXPERIMENTAL | Participant will receive a dose A of GLPG3667 capsules orally once daily (q.d.) for 48 weeks. |
| GLPG3667 - Treatment B | EXPERIMENTAL | Participant will receive a dose B of GLPG3667 capsules orally (q.d.) for 48 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participant will receive placebo matched to GLPG3667 capsules orally q.d for 48 weeks. |
| Name | Type | Description |
|---|---|---|
| GLPG3667 | DRUG | Capsule |
| Placebo | DRUG | Capsule |
Key Inclusion Criteria: 1. Participant with documented diagnosis of SLE as defined by the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria with a disease diagnosed ≥24 weeks before the screening visit. 2. Participant has a total Systemic...